Neurobiology of Disease (Dec 2001)
Formation of Filamentous Tau Aggregations in Transgenic Mice Expressing V337M Human Tau
- Kentaro Tanemura,
- Takumi Akagi,
- Miyuki Murayama,
- Naomi Kikuchi,
- Ohoshi Murayama,
- Tsutomu Hashikawa,
- Yuji Yoshiike,
- Jung-Mi Park,
- Keiko Matsuda,
- Shinobu Nakao,
- Xiaoyan Sun,
- Shinji Sato,
- Haruyasu Yamaguchi,
- Akihiko Takashima
Affiliations
- Kentaro Tanemura
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Takumi Akagi
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Miyuki Murayama
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Naomi Kikuchi
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Ohoshi Murayama
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Tsutomu Hashikawa
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Yuji Yoshiike
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Jung-Mi Park
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Keiko Matsuda
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Shinobu Nakao
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Xiaoyan Sun
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Shinji Sato
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Haruyasu Yamaguchi
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Akihiko Takashima
- Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Neural Architecture, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan; Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan; Gunma University School of Health Sciences, Gunma, Japan
- Journal volume & issue
-
Vol. 8,
no. 6
pp. 1036 – 1045
Abstract
Formation of neurofibrillary tangles (NFTs) is the most common feature in several neurodegenerative diseases, including Alzheimer's disease (AD). Here we report the formation of filamentous tau aggregations having a β-sheet structure in transgenic mice expressing mutant human tau. These mice contain a tau gene with a mutation of the frontotemporal dementia parkinsonism (FTDP-17) type, in which valine is substituted with methionine residue 337. The aggregation of tau in these transgenic mice satisfies all histological criteria used to identify NFTs common to human neurodegenerative diseases. These mice, therefore, provide a preclinical model for the testing of therapeutic drugs for the treatment of neurodegenerative disorders that exhibit NFTs.
